Three isoenzymes of enolase occur in man and in other mammals. Evidence has accumulated from biochemical, genetic, somatic cell genetic and molecular genetic studies that there are at least three different genes (see [ 1 I ). Various nomenclatures have been used previously and these have been clarified recently [ 1 I. 1 ,ocus E N 0 1 expresses a subunit, locus E N 0 2 expresses y subunit and locus E N 0 3 expresses / 3 subunit: enolase subunits form homo-o r heterodirners. aa-enolase also being known as non-neuronal enolase (NNE), PP-enolase as muscle-specific enolase (MSE) and y y-enolase as neuron-specific enolase (NSE). Many neurons express predominantly y subunit, whereas some neurons and various neuroendocrine cells express a mixture of y and a subunits, and skeletal and cardiac muscle express predominantly / 3 subunit [ 2, 31: in ziivo all possible diniers except P y have been Abbreviations used: MSE. muscle-specific enolase; NNE, non-neuronal enolase; NSE, neuron-specific enolase; I U l , ubiquitin C-terminal hydrolase. observed. T h e level of expression of / 3 subunit seems to correlate with fibre type, being higher in glycolytic (type 2) fibres [ 3 ] .
T h e expression of a unique isoenzyme of enolase in neurons first became clear when the brain-specific protein 14-3-2 identified by onedimensional PAGE was shown to possess enolase activity [4] . More recently, the application of twodimensional electrophoresis to the comparison of different human tissues in a search for novel cellular markers resulted in the identification of a protein (designated PGP9.5) specific to the cytosol of almost all neuronal types [S] at a concentration similar to, or higher than, that of NSE (1 -5% w/w of total soluble protein). Protein and cDNA sequencing [6] , followed by database entry of an homologous protein [7] , resulted in the identification of PGP9.5 as the neuron-specific member amongst (apparently) three similar isoenzymes acting as ubiquitin C-terminal hydrolases. Further consideration of PGP9.5 expression as a model for neuronal gene activation is given in another paper in this issue [8] . Although there may be 50000 human genes [9] , there can be few gene products expressed at levels comparable with NSE or PGP9.5 and marking most neurons.
The existence of isoproteins and isogenes can have advantages at one or more levels (e.g. enzymological, regulation, control of gene expression) and many different examples have been identified (for an overview, see [ 101). The advent of molecular cloning has enabled more detailed investigations of structural differences between isoproteins and of the evolution and differential regulation of members of a gene family. Such investigations should enable a better understanding of NSE and PGP9.5 at the protein and gene levels, in the context of both the evolution and regulation of their gene families, in relative terms in their context within the neuron, and also in their clinical application as cell-specific markers. I Iere, some recent work in this laboratory is reviewed.
We have previously described protein sequence and cI)NA analysis for human NSE and PGP9.S [h, I l l , and also isolation and characterization of human genomic clones representing both PGP9. 5 [18] and E N 0 2 [ 191 appears to complete the set for active enolase loci in man. Parallel sets of investigations have taken place for rat (refs in [ZO] ) and, less completely, for several other species. This collection of data and cloned DNA fragments has opened the way for many possible investigations. Two avenues are considered here.
Structural and immunochemical aspects of the protein, NSE
The solubility in plasma, patterns of cellular specificity and high level of expression of major isoenzymes lends them, in the field of clinical biochemistry, to development as diagnostic markers. Indeed, this was one of the original reasons for the discovery of PGP9. 5 [25] . In this instance, at least, it is possible that the tumours arise from neuroendocrine cells lining the normal lung [25] . Small cell lung cancer accounts for 24% of all lung tumours, which themselves account for 26.8% of all cancer deaths in the U.K. [26] . At present there are no established biochemical markers either for screening, diagnosis, monitoring or prognosis. In addition little is understood of the genetic regulation of small cell tumours. Conventional polyclonal immunoassays have been used to monitor tumourderived NSE in the serum of patients undergoing therapy [ 241. More recently, several monoclonal antibodies to NSE have been described .
W e have reconstructed a full-length NSE cDNA from partial-length cDNA clones, first to adopt a more directly structural approach to further the immunochemical analysis of NSE, by antigen expression, and secondly to enable in vitro expression and analysis of functional NSE. In the long term the latter approach will be of particular interest with respect to the neuronal environment, for example in relation to the known chloride resistance . Selected restriction fragment subclones and clones generated by sonication-shotgun cloning were also analysed. Standard colony blotting and Western blotting of SDS-PAGE of colony extracts using several rabbit and sheep polyclonal antisera to human NSE were employed to analyse antigenic and epitope regions in native and recombinant NSE. The results of these studies are shown in Fig. 1 .
The recent determination at 2.25A of the crystal structure of Saccharomyces cermisiae enolase-1 [34] and the direct alignment possible between human enolases and this sequence [14] make it possible to try to interpret our immunochemical data and human sequence comparisons in , -~ ----, noted that the main sites of sequence difference between the three human enolase isoenzymes involve regions that correspond (using direct sequence alignment) with yeast enolase-1 crystal structural elements, 9, I, J, A, 13, C, I), E and the Cterminus. In the yeast enolase-1 crystal structure, a-helices A-H surround /3-strands 1-8 to form an a/3 barrel with the active site at its core, and ahelices I-K and /3-strands 0-1 1 form a separate Nterminal domain. The four main epitope/antigenic regions of NSE (Fig. 1) seem to be quite discretely placed and span, respectively: the loop between /3-strand 1 I , helix I and helix J (E 1); the range through helices A and B (E2); helix C and adjacent loop (E3); and helix H and the C-terminus (E4). The approximate correspondence of sequence variability between isoenzymes with NSE epitope regions probably indicates that they both represent mainly 'surface' residues, which both act more accessibly as antigenic targets and are more permissible to evolutionary mutational divergence of isoenzyme sequences. Regions of coincidence of antigenicity with isoenzyme sequence differences . As both families appear to contain three active members. it is tempting to speculate that a common evolutionary mechanism was involved: one candidate event would be a tetraploidization which may have influenced much of the mammalian genome 1-17], EN01 maps to human chromosome lp, EN02 to human chromosome 12p and E N 0 3 to human chromosome 17p (see genes and UCH genes are known to have diverged both at the protein and coding sequence levels (see above). In addition, it has also been proven that (Fig. 2) . Exon XI1 also contains the stop codon, mRNA 3' non-coding sequence and cleavage-polyadenylation signal in each instance. No alignment can be made between the 3' non-coding sequences of ENO1, E N 0 2 and 
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